Chronic Myeloid Leukemia: Optimizing Use of TKIs to Individualize Treatment Across the Disease Spectrum

Get the latest evidence on optimizing the use of TKI-based therapies for patients with chronic myeloid leukemia, including strategies to personalize and sequence treatment to prevent disease progression or overcome resistance, reduce toxicities, and incorporate patient preferences in this text module with accompanying downloadable slides.

Share

Program Content

No activities added yet

No activities added yet

No activities added yet

Provided by

ProCE Banner

Provided by Clinical Care Options, LLC

Supporters

Supported by educational grants from Bristol Myers Squibb and Novartis Pharmaceuticals Corporation.

Bristol Myers Squibb

Novartis Pharmaceuticals Corporation